Abstract 3901
Background
Efficacy data of treatment sequences in mRCC are rare. In the Czech Republic, data on efficacy and safety of all targeted therapies for mRCC are collected in the RENIS patient registry. Thus, RENIS provides data from the real-world clinical practice. The aim of this study was to compare outcomes of selected treatment sequences in mRCC while adjusting for differences in patient characteristics using inverse propensity score weighting method (IPWS).
Methods
Data of mRCC patients treated using most common treatment sequences were collected in RENIS between 06/2007 and 02/2018. Overall survival (OS) and progression free survival (PFS) were evaluated. Baseline characteristics were balanced using IPWS. The propensity score was evaluated with nominal logistic model to balance Eastern Cooperative Oncology Group (ECOG) performance status, time from diagnosis to first treatment, nephrectomy, Memorial Sloan-Kettering Cancer Center (MSKCC) score, and age. Median and confidence intervals (CI) were derived from IPWS weighted Kaplan-Meier curves that were compared using log-rank test.
Results
Overall, 745 patients in five treatment sequences were included and analysed. Differences in OS were significant (p < 0.001) with sunitinib→axitinib→everolimus and sunitinib→axitinib sequences associated with improved survival over other sequences. These differences could be also linked to time when these drugs were introduced. PFS did not differ between sunitinib and pazopanib used as first line treatments (p = 0.44) but the PFS in the second line differed significantly (p = 0.035) (Table). Table: Results of OS and PFS for examined sequences computed using inverse propensity score weighting. Sunitinib → Axitinib → Everolimus sequence should be assessed with caution due to immortal time bias.Table: 892P
| Parameter | Treatment sequence | n | Median | 95% CI for median | p | |
|---|---|---|---|---|---|---|
| Lower limit | Upper limit | |||||
| OS (months) | Sunitinib → Everolimus | 312 | 26.3 | 23.8 | 29.0 | <0.001 |
| Sunitinib → Axitinib | 154 | 47.6 | 31.3 | 50.5 | ||
| Sunitinib → Axitinib → Everolimus† | 114 | 46.0 | 44.7 | 50.9 | ||
| Pazopanib → Everolimus | 74 | 32.9 | 30.9 | 33.8 | ||
| Pazopanib → Sunitinib | 91 | 27.2 | 26.7 | 28.8 | ||
| PFS 1st line (months) | Sunitinib | 580 | 10.2 | 9.8 | 10.8 | 0.440 |
| Pazopanib | 165 | 9.2 | 8.5 | 10.0 | ||
| PFS 2nd line (months) | Sunitinib → Everolimus | 312 | 5.8 | 5.1 | 6.3 | 0.035 |
| Sunitinib → Axitinib | 268 | 6.4 | 6.0 | 7.1 | ||
| Pazopanib → Everolimus | 74 | 5.1 | 4.1 | 5.5 | ||
| Pazopanib → Sunitinib | 91 | 5.3 | 5.1 | 7.1 |
Conclusions
Improved outcomes were associated with sequences using second-line axitinib over those using second-line sunitinib or everolimus in a cohort of patients from a national registry.
Clinical trial identification
Legal entity responsible for the study
Jindrich Finek.
Funding
Value Outcomes.
Editorial Acknowledgement
Disclosure
J. Finek: Honoraria: Amgen, BMS, Roche, Bayer, Teva, MSD, Merck, Sanofi, Pierre Fabre. R. Demlova: Honoraria for lectures: Bayer. K. Kopeckova: Honoraria for lectures: Novartis; Travel grants: Pfizer, Bayer. T. Buchler: Honoraria for advisory boards and/or lectures: Novartis, Pfizer, Bayer, Roche. B. Melichar: Honoraria for advisory boards and/or lectures: Novartis, Pfizer, Glaxo Smith Kline, Roche, Bayer. A. Poprach: Honoraria for lectures: Novartis, Bristol-Myers Squibb, Roche, Bayer. T. Hrnciarova, T. Mlcoch, T. Dolezal: Employee of Value Outcomes. All other authors have declared no conflicts of interest.
Resources from the same session
4742 - Ki67 as an important predictor for Oncotype Dx Recurrence score risk groups in Early Breast cancer
Presenter: Fernando Namuche
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4697 - Genetic signatures always suggest undertreatment? Experience with PAM51
Presenter: Carolina Sales
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3158 - Significance of receptors expression, mitotic index and Ki67 in breast cancer patients with Nottingham Prognostic Index (NPI) poor prognosis score
Presenter: Mejri Nesrine
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3838 - Subgroup analyses of efficacy from a phase III study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab in early breast cancer patients
Presenter: Javier Cortes Castan
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
715 - Autoimmunity and benefit from trastuzumab treatment in breast cancer: results from the HERA phase 3 trial
Presenter: Amir Sonnenblick
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2388 - Impact of hormone receptor status in HER2+ early breast cancer: a paradigm shift in the trastuzumab era
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3742 - Sefety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The french HERMIONE non-interventional prospective study
Presenter: jean-philippe Jacquin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3647 - Real-life data on the cardiac toxicity of adjuvant fixed-dose subcutaneous trastuzumab in HER2-positive breast cancer.
Presenter: Rita De Sanctis
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3837 - Comprehensive evaluation of the pharmacokinetic profiles of SB3 and reference trastuzumab
Presenter: Xavier Pivot
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
1692 - The impact of neoadjuvant dual HER2 targeting with Pertuzumab and Trastuzumab on pathological complete response (pCR) rates: Kent Oncology Centre (KOC) experience
Presenter: Samantha Forner
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract